{"id":64328,"date":"2026-04-30T15:02:53","date_gmt":"2026-04-30T07:02:53","guid":{"rendered":"https:\/\/flcube.com\/?p=64328"},"modified":"2026-04-30T15:02:54","modified_gmt":"2026-04-30T07:02:54","slug":"teva-to-acquire-emalex-biosciences-for-700m-adding-registration-ready-tourette-syndrome-drug-ecopipam","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64328","title":{"rendered":"Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam"},"content":{"rendered":"\n<p><strong>Teva Pharmaceuticals Industries Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/TEVA:NYSE\">NYSE: TEVA<\/a>) and <strong>Emalex Biosciences<\/strong> announced a <strong>definitive acquisition agreement<\/strong> under which Teva will acquire Emalex, including its lead asset <strong>ecopipam<\/strong>, a <strong>registration-ready selective dopamine D1 receptor antagonist<\/strong> for the treatment of <strong>pediatric Tourette syndrome<\/strong>. The transaction, valued at <strong>USD 700 million upfront<\/strong> plus <strong>up to USD 200 million in commercial milestones<\/strong>, is expected to close in <strong>Q3 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Teva Pharmaceuticals (NYSE: TEVA)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Emalex Biosciences<\/td><\/tr><tr><td><strong>Lead Asset<\/strong><\/td><td>Ecopipam \u2013 selective dopamine D1 receptor antagonist<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Pediatric Tourette syndrome<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 700 million<\/td><\/tr><tr><td><strong>Contingent Consideration<\/strong><\/td><td>Up to USD 200 million in commercial milestones + royalties on global net sales<\/td><\/tr><tr><td><strong>Expected Closing<\/strong><\/td><td>Q3 2026<\/td><\/tr><tr><td><strong>Regulatory Timeline<\/strong><\/td><td>NDA submission anticipated in H2 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-asset-profile-amp-clinical-data\">Asset Profile &amp; Clinical Data<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: <strong>Selective dopamine D1 receptor antagonist<\/strong> \u2013 novel approach targeting specific dopamine pathway implicated in Tourette syndrome pathophysiology<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: <strong>Registration-ready<\/strong> following successful Phase 3 trial completion<\/li>\n\n\n\n<li><strong>Phase 3 Results<\/strong>: Demonstrated <strong>statistically significant improvement<\/strong> on primary efficacy endpoint in children with Tourette syndrome<\/li>\n\n\n\n<li><strong>Therapeutic Innovation<\/strong>: First-in-class mechanism addressing unmet need in pediatric movement disorder market<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Oral therapy designed for pediatric population<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-unmet-need\">Market Context &amp; Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Tourette Syndrome Prevalence<\/strong><\/td><td>Affects approximately 1% of school-age children globally, with severe cases requiring pharmacological intervention<\/td><\/tr><tr><td><strong>Current Treatment Landscape<\/strong><\/td><td>Limited options including antipsychotics (risperidone, aripiprazole) with significant side effect profiles<\/td><\/tr><tr><td><strong>Unmet Medical Need<\/strong><\/td><td>High demand for targeted therapies with improved safety and tolerability profiles for pediatric patients<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>Estimated $500-700 million global market potential for first-in-class Tourette syndrome therapy<\/td><\/tr><tr><td><strong>Regulatory Incentives<\/strong><\/td><td>Potential for pediatric exclusivity and orphan drug designation enhancing commercial protection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-financial-implications\">Strategic Rationale &amp; Financial Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-teva-pharmaceuticals\">For Teva Pharmaceuticals<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Diversification<\/strong>: Expands beyond generics into innovative CNS therapeutics with premium pricing potential<\/li>\n\n\n\n<li><strong>CNS Franchise Enhancement<\/strong>: Complements existing neurology portfolio and leverages established commercial infrastructure<\/li>\n\n\n\n<li><strong>Innovation Pipeline<\/strong>: Represents strategic shift toward proprietary assets with meaningful clinical differentiation<\/li>\n\n\n\n<li><strong>Financial Impact<\/strong>: Modest upfront investment relative to potential peak sales; milestone structure limits downside risk<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-deal-structure-advantages\">Deal Structure Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Risk-Mitigated Payment<\/strong>: Majority upfront with significant contingent consideration tied to commercial success<\/li>\n\n\n\n<li><strong>Global Rights<\/strong>: Royalty structure on worldwide net sales provides long-term revenue participation<\/li>\n\n\n\n<li><strong>Regulatory De-Risking<\/strong>: Phase 3 success and imminent NDA filing reduce development uncertainty<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-amp-commercial-outlook\">Competitive Landscape &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage<\/strong>: Novel D1 mechanism creates significant differentiation from existing antipsychotic-based treatments<\/li>\n\n\n\n<li><strong>Pediatric Focus<\/strong>: Specialized development program addresses unique needs of child and adolescent patient population<\/li>\n\n\n\n<li><strong>Payer Dynamics<\/strong>: Premium pricing justified by improved safety profile and targeted mechanism of action<\/li>\n\n\n\n<li><strong>Commercial Readiness<\/strong>: Teva&#8217;s established CNS commercial team can rapidly deploy upon regulatory approval<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong>: Successful U.S. launch could support international regulatory filings and market expansion<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding transaction completion, regulatory timelines, clinical development outcomes, and commercial potential. Actual results may differ due to risks including regulatory decisions, competitive developments, integration challenges, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Emalex Biosciences announced a definitive acquisition agreement under&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4723,1072,1071],"class_list":["post-64328","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-emalex-biosciences","tag-nyse-teva","tag-teva-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Emalex Biosciences announced a definitive acquisition agreement under which Teva will acquire Emalex, including its lead asset ecopipam, a registration-ready selective dopamine D1 receptor antagonist for the treatment of pediatric Tourette syndrome. The transaction, valued at USD 700 million upfront plus up to USD 200 million in commercial milestones, is expected to close in Q3 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64328\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam\" \/>\n<meta property=\"og:description\" content=\"Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Emalex Biosciences announced a definitive acquisition agreement under which Teva will acquire Emalex, including its lead asset ecopipam, a registration-ready selective dopamine D1 receptor antagonist for the treatment of pediatric Tourette syndrome. The transaction, valued at USD 700 million upfront plus up to USD 200 million in commercial milestones, is expected to close in Q3 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64328\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T07:02:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-30T07:02:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64328#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64328\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam\",\"datePublished\":\"2026-04-30T07:02:53+00:00\",\"dateModified\":\"2026-04-30T07:02:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64328\"},\"wordCount\":480,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Emalex Biosciences\",\"NYSE: TEVA\",\"Teva Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64328#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64328\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64328\",\"name\":\"Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-30T07:02:53+00:00\",\"dateModified\":\"2026-04-30T07:02:54+00:00\",\"description\":\"Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Emalex Biosciences announced a definitive acquisition agreement under which Teva will acquire Emalex, including its lead asset ecopipam, a registration-ready selective dopamine D1 receptor antagonist for the treatment of pediatric Tourette syndrome. The transaction, valued at USD 700 million upfront plus up to USD 200 million in commercial milestones, is expected to close in Q3 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64328#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64328\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64328#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam - Insight, China&#039;s Pharmaceutical Industry","description":"Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Emalex Biosciences announced a definitive acquisition agreement under which Teva will acquire Emalex, including its lead asset ecopipam, a registration-ready selective dopamine D1 receptor antagonist for the treatment of pediatric Tourette syndrome. The transaction, valued at USD 700 million upfront plus up to USD 200 million in commercial milestones, is expected to close in Q3 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64328","og_locale":"en_US","og_type":"article","og_title":"Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam","og_description":"Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Emalex Biosciences announced a definitive acquisition agreement under which Teva will acquire Emalex, including its lead asset ecopipam, a registration-ready selective dopamine D1 receptor antagonist for the treatment of pediatric Tourette syndrome. The transaction, valued at USD 700 million upfront plus up to USD 200 million in commercial milestones, is expected to close in Q3 2026.","og_url":"https:\/\/flcube.com\/?p=64328","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T07:02:53+00:00","article_modified_time":"2026-04-30T07:02:54+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64328#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64328"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam","datePublished":"2026-04-30T07:02:53+00:00","dateModified":"2026-04-30T07:02:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64328"},"wordCount":480,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Emalex Biosciences","NYSE: TEVA","Teva Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64328#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64328","url":"https:\/\/flcube.com\/?p=64328","name":"Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-30T07:02:53+00:00","dateModified":"2026-04-30T07:02:54+00:00","description":"Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Emalex Biosciences announced a definitive acquisition agreement under which Teva will acquire Emalex, including its lead asset ecopipam, a registration-ready selective dopamine D1 receptor antagonist for the treatment of pediatric Tourette syndrome. The transaction, valued at USD 700 million upfront plus up to USD 200 million in commercial milestones, is expected to close in Q3 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64328#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64328"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64328#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64328"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64328\/revisions"}],"predecessor-version":[{"id":64330,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64328\/revisions\/64330"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}